卵巣がん診断の世界市場

卵巣がん診断の世界市場は2030年までに58億米ドルに達する見込み

2024年に47億米ドルと推定される卵巣がん診断の世界市場は、2024〜2030年の分析期間においてCAGR 3.5％で成長し、2030年には58億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである上皮性腫瘍は、CAGR 4.4％を記録し、分析期間終了時には23億米ドルに達すると予測されます。生殖細胞腫瘍セグメントの成長率は、分析期間中CAGR 2.5%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 6.7％で成長すると予測

米国の卵巣がん診断市場は2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と2.8%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界の卵巣がん診断市場- 主要動向と促進要因のまとめ

卵巣がん診断市場が勢いを増す理由とは？

卵巣がん診断市場は、卵巣がんの有病率の上昇と早期発見の必要性の高まりにより、力強い成長を遂げています。卵巣がんは、初期段階では無症状であるため、依然として最も致死率の高い婦人科悪性腫瘍の1つであり、生存率を向上させるためにはタイムリーな診断が不可欠です。卵巣がん検診に対する認識が高まるにつれ、ヘルスケアプロバイダーや研究者は、より早期で治療可能な段階で病気を発見するための高度な診断ツールに投資しています。

さらに、政府のイニシアチブ、がん啓発プログラム、バイオマーカーに基づく検査の進歩が市場拡大を後押ししています。遺伝子検査法の改善とリキッドバイオプシー技術の採用の増加により、卵巣がん診断はより正確で、利用しやすく、侵襲性が低くなってきています。

リキッドバイオプシーとAI主導型スクリーニングは卵巣がん診断をどのように変革するか？

リキッドバイオプシー技術の開発は、循環腫瘍DNA（ctDNA）とRNAマーカーによる非侵襲的検出を可能にすることで、卵巣がん診断に革命をもたらしています。これらの検査は、従来の生検法に代わる有望な選択肢を提供し、がんの進行や治療効果をリアルタイムでモニタリングすることを可能にしています。

AIを搭載した診断ツールも、画像スキャン、遺伝子データ、病理組織学的サンプルを分析することで、早期発見率を向上させています。機械学習アルゴリズムは卵巣悪性腫瘍を示すパターンを特定し、診断ミスを減らし、より迅速な臨床判断を可能にします。卵巣がん診断にAIが統合されることで、疾患検出の精度と効率が大幅に向上することが期待されます。

個別化医療と遺伝子検査は市場機会を拡大するか？

個別化医療の台頭は卵巣がん診断の形を変えつつあり、遺伝子検査は発症リスクの高い個人を特定する上で重要な役割を果たしています。BRCA1およびBRCA2変異検査は、多遺伝子パネル検査とともに、標的を絞ったスクリーニングと予防戦略を可能にしています。

製薬企業や診断ラボは、個人の遺伝子プロファイルに基づいて治療の決定を導くコンパニオン診断にますます力を注いでいます。精密医療と標的治療の拡大は、特定の患者集団に合わせた高度な診断ソリューションの需要をさらに促進しています。

卵巣がん診断市場の成長の原動力は？

卵巣がん診断市場の成長は、早期発見に対する意識の高まり、リキッドバイオプシーやAIを活用したスクリーニングの進歩、個別化医療における遺伝子検査の役割の拡大など、いくつかの要因によってもたらされます。非侵襲的診断技術へのシフトは、卵巣がん検出をより身近で効果的なものにしています。

さらに、がん研究に対する政府助成金の増加、新規バイオマーカーの開発、集団全体の検診プログラムの重視の高まりが市場の成長を加速させています。診断技術が進化し続けるにつれて、卵巣がんの検出はより正確かつ救命的なものになると予想されます。

セグメント

がん種（上皮性腫瘍、生殖細胞腫瘍、間質細胞腫瘍、その他のがん種）;診断方法（画像診断、血液検査、生検、その他の診断方法）;エンドユーザー（病院検査室エンドユーザー、がん診断センターエンドユーザー、調査エンドユーザー、その他のエンドユーザー）

調査対象企業の例

• Abbott Laboratories
• Agilent Technologies
• Aspira Women's Health
• Becton, Dickinson and Company（BD）
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Foundation Medicine
• GE Healthcare
• GRAIL, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Merck KGaA
• Myriad Genetics, Inc.
• NanoString Technologies
• Oncocyte Corporation
• PerkinElmer Inc.
• Quest Diagnostics
• Roche Holding AG
• Siemens Healthineers
• Thermo Fisher Scientific

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Ovarian Cancer Diagnostics Market to Reach US$5.8 Billion by 2030

The global market for Ovarian Cancer Diagnostics estimated at US$4.7 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Epithelial Tumor, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Germ Cell Tumor segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 6.7% CAGR

The Ovarian Cancer Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Ovarian Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Is the Ovarian Cancer Diagnostics Market Gaining Momentum?

The ovarian cancer diagnostics market is witnessing strong growth due to the rising prevalence of ovarian cancer and the increasing need for early detection. Ovarian cancer remains one of the most lethal gynecological malignancies due to its asymptomatic nature in early stages, making timely diagnosis critical for improving survival rates. As awareness of ovarian cancer screening grows, healthcare providers and researchers are investing in advanced diagnostic tools to detect the disease at an earlier and more treatable stage.

Additionally, government initiatives, cancer awareness programs, and advancements in biomarker-based testing are driving market expansion. With improved genetic testing methods and the increasing adoption of liquid biopsy techniques, ovarian cancer diagnostics are becoming more accurate, accessible, and less invasive.

How Are Liquid Biopsy and AI-Driven Screening Transforming Ovarian Cancer Diagnosis?

The development of liquid biopsy techniques is revolutionizing ovarian cancer diagnostics by enabling non-invasive detection through circulating tumor DNA (ctDNA) and RNA markers. These tests are offering a promising alternative to traditional biopsy procedures, allowing for real-time monitoring of cancer progression and treatment response.

AI-powered diagnostic tools are also improving early detection rates by analyzing imaging scans, genetic data, and histopathological samples. Machine learning algorithms can identify patterns indicative of ovarian malignancies, reducing diagnostic errors and enabling faster clinical decision-making. The integration of AI in ovarian cancer diagnostics is expected to significantly enhance accuracy and efficiency in disease detection.

Are Personalized Medicine and Genetic Testing Expanding Market Opportunities?

The rise of personalized medicine is reshaping ovarian cancer diagnostics, with genetic testing playing a crucial role in identifying individuals at high risk of developing the disease. BRCA1 and BRCA2 mutation testing, along with multi-gene panel testing, is allowing for targeted screening and preventive strategies.

Pharmaceutical companies and diagnostic labs are increasingly focusing on companion diagnostics that guide treatment decisions based on an individual’s genetic profile. The expansion of precision medicine and targeted therapies is further driving demand for advanced diagnostic solutions tailored to specific patient populations.

What’s Driving the Growth of the Ovarian Cancer Diagnostics Market?

The growth in the ovarian cancer diagnostics market is driven by several factors, including increasing awareness of early detection, advancements in liquid biopsy and AI-powered screening, and the expanding role of genetic testing in personalized medicine. The shift toward non-invasive diagnostic techniques is making ovarian cancer detection more accessible and effective.

Additionally, rising government funding for cancer research, the development of novel biomarkers, and the growing emphasis on population-wide screening programs are accelerating market growth. As diagnostic technologies continue to evolve, ovarian cancer detection is expected to become more precise and life-saving.

SCOPE OF STUDY:

The report analyzes the Ovarian Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Other Cancer Types); Diagnostic Method (Imaging, Blood Tests, Biopsy, Other Diagnostic Methods); End-Use (Hospital Laboratories End-Use, Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Agilent Technologies
• Aspira Women's Health
• Becton, Dickinson and Company (BD)
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Foundation Medicine
• GE Healthcare
• GRAIL, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Merck KGaA
• Myriad Genetics, Inc.
• NanoString Technologies
• Oncocyte Corporation
• PerkinElmer Inc.
• Quest Diagnostics
• Roche Holding AG
• Siemens Healthineers
• Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Ovarian Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence and Late Detection of Ovarian Cancer Throw the Spotlight on Early Diagnostic Solutions
  • Advancements in Liquid Biopsy and Biomarker Technology Accelerate Innovation in Diagnostics
  • Growing Awareness Campaigns and Routine Screening Programs Drive Adoption
  • Shift Toward Personalized Medicine Strengthens Business Case for Genomic Testing
  • High Mortality Rates Propel Demand for High-Sensitivity, Non-Invasive Detection Tools
  • Integration of AI in Image Analysis Supports Clinical Decision-Making in Diagnostics
  • Government Grants and Research Funding Sustain Innovation in Early Detection Platforms
  • Collaborations Between Pharma and Diagnostics Firms Accelerate Co-Development Strategies
  • Expansion of Direct-to-Consumer Genetic Testing Opens New Market Channels
  • Clinical Trial Expansion Fuels Demand for Companion Diagnostics in Oncology
  • Health System Digitization and Data Integration Improve Test Accessibility and Utility
  • Reimbursement Expansion for Advanced Diagnostics Drives Market Uptake
  • Growing Use of Multi-Cancer Early Detection Panels Enhances Ovarian Test Value
  • Diagnostic Labs and Startups Attract Investment for Point-of-Care Development
  • Regulatory Approvals of Novel Testing Kits Propel Market Entry in Developed and Emerging Markets
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ovarian Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Ovarian Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Epithelial Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Epithelial Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Epithelial Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Germ Cell Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Germ Cell Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Germ Cell Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Stromal Cell Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Stromal Cell Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Stromal Cell Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Cancer Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Cancer Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Cancer Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospital Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Blood Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Diagnostic Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Diagnostic Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Diagnostic Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• JAPAN
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• CHINA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• EUROPE
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Ovarian Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• FRANCE
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• GERMANY
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• INDIA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Ovarian Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Ovarian Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• AFRICA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030

IV. COMPETITION